Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer (Q35977154)

11 August 2017

Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer (English)

1 reference

11 August 2017

1 reference

2

Nancy L Keating

1 reference

11 August 2017

Marianne Ulcickas Yood

6

object named as

Marianne Ulcickas Yood

1 reference

11 August 2017

4

Reina Haque

1 reference

11 August 2017

Huei-Ting Tsai

1

1 reference

11 August 2017

Stephen K Van Den Eeden

3

1 reference

11 August 2017

Andrea E Cassidy-Bushrow

5

1 reference

11 August 2017

Matthew R Smith

7

1 reference

11 August 2017

Arnold L Potosky

8

1 reference

11 August 2017

language of work or name

English

0 references

publication date

15 December 2014

1 reference

11 August 2017

1 reference

11 August 2017

193

1 reference

11 August 2017

6

1 reference

11 August 2017

1956-1962

1 reference

Androgen deprivation therapy complications

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Standards of medical care in diabetes--2014

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

HbA1c for diagnosis of type 2 diabetes. Is there an optimal cut point to assess high risk of diabetes complications, and how well does the 6.5% cutoff perform?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Androgen-deprivation therapy and diabetes control among diabetic men with prostate cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Metabolic complications of androgen deprivation therapy for prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer?

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Metabolic sequelae associated with androgen deprivation therapy for prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Survival following primary androgen deprivation therapy among men with localized prostate cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Guideline for the management of clinically localized prostate cancer: 2007 update.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Building a research consortium of large health systems: the Cancer Research Network.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Dyslipidemia, Hypertension and Diabetes Metaflammation. A Unique Mechanism for 3 Risk Factors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Surveillance of demographic characteristics and health behaviors among adult cancer survivors--Behavioral Risk Factor Surveillance System, United States, 2009.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Insulin sensitivity during combined androgen blockade for prostate cancer

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect.

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Changes in body composition during androgen deprivation therapy for prostate cancer

24 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4543371

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

24 September 2018

1 reference

12 December 2020

Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer

1 reference

12 December 2020

Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

1 reference

12 December 2020

10.1016/J.JURO.2014.12.027

Identifiers

DOI

1 reference

11 August 2017

1 reference

11 August 2017

1 reference